PRF1 and prostate cancer: Likewise, we determined that using these treatments in combination with anti-TIGIT increases and maintains the expression of some factors such as NKp46 and secretion of granzyme A, granzyme B, perforin, and granulysin which may regulate cytotoxicity against DU145 prostate cancer cells.